Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacies against Plasmodium chabaudi malaria based on prechallenge antibody responses

Clinical and Vaccine Immunology

Volumn 16, Issue 3, 2009, Pages 293-302

  Lynch, Michelle M ^a   Cernetich Ott, Amy ^a   Weidanz, William P ^a,b   Burns Jr , James M ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; APICAL MEMBRANE ANTIGEN 1; EPITOPE; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; QUIL A; SUBUNIT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG FORMULATION; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNIZATION; MALE; MOUSE; NONHUMAN; PARASITEMIA; PLASMODIUM CHABAUDI; PLASMODIUM CHABAUDI INFECTION; PLASMODIUM FALCIPARUM; PREDICTION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FOLDING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, B-LYMPHOCYTE; MALARIA; MALARIA VACCINES; MALE; MEMBRANE PROTEINS; MEROZOITE SURFACE PROTEIN 1; MICE; MICE, INBRED C57BL; PARASITEMIA; PLASMODIUM CHABAUDI; PROTOZOAN PROTEINS; VACCINATION;

EID: 61949452740     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00230-08     Document Type: Article

References (57)

1. Alonso, P. L., J. Sacarlal, J. J. Aponte, A. Leach, E. Macete, P. Aide, B. Sigauque, J. Milman, I. Mandomando, Q. Bassat, C. Guinovart, M. Espasa, S. Corachan, M. Lievens, M. M. Navia, M. C. Dubois, C. Menendez, F. Dubovsky, J. Cohen, R. Thompson, and W. R. Ballou. 2005. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blinded extended follow-up of a randomized controlled trial. Lancet 366:2012-2018.
2. Anders, R. A., P. E. Crewther, S. Edwards, M. Margetts, M. L. S. M. Matthew, B. Pollock, and D. Pye. 1997. Immunization with recombinant AMA1 protects mice against infection with Plasmodium chabaudi. Vaccine 16:240-247.
3. Aponte, J. J., P. Aide, M. Renom, I. Mandomando, Q. Bassat, J. Sacarlal, M. N. Manaca, S. Lafuente, A. Barbosa, A. Leach, M. Lievens, J. Vekemans, B. Sigauque, M. C. Dubois, M. A. Demoitié, M. Sillman, B. Savarese, J. G. McNeil, E. Macete, W. R. Ballou, J. Cohen, and P. L. Alonso. 2007. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomized controlled phase I/IIb trial. Lancet 370:1543-1551.
4. Burns, J. M., Jr., P. R. Flaherty, P. Nanavati, and W. P. Weidanz. 2004. Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen-1 and merozoite surface protein-1 in the absence of gamma interferon or interleukin-4. Infect. Immun. 72:5605-5612.
5. Burns, J. M., Jr., P. R. Flaherty, M. M. Romero, and W. P. Weidanz. 2003. Immunization against Plasmodium chabaudi malaria using combined formulations of apical membrane antigen-1 and merozoite surface protein-1. Vaccine 21:1843-1852.
6. Burns, J. M., Jr., W. R. Majarian, J. F. Young, T. M. Daly, and C. A. Long. 1989. A protective monoclonal antibody recognizes an epitope in the Cterminal cysteine-rich domain in the precursor of the major merozoite surface antigen of the rodent malarial parasite Plasmodium yoelii. J. Immunol. 143:2670-2676.
7. Chang, S. P., S. E. Case, W. L. Gosnell, A. Hashimoto, K. J. Kramer, L. Q. Tam, C. Q. Hashiro, C. M. Nikaido, H. L. Gibson, C. T. Lee-Ng, P. J. Barr, B. T. Yokota, and G. S. N. Hui. 1996. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infect. Immun. 64:253-261.
8. Chappel, J. A., and A. A. Holder. 1993. Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognize the first growth factor-like domain of merozoite surface protein-1. Mol. Biochem. Parasitol. 60:303-311.
9. Coley, A. M., K. Parisi, R. Masciantonio, J. Hoeck, J. L. Casey, V. J. Murphy, K. S. Harris, A. H. Batchelor, R. F. Anders, and M. Foley. 2006. The most polymorphic residue on Plasmodium falciparum apical membrane antigen 1 determines binding of an invasion-inhibitory antibody. Infect. Immun. 74:2628-2636.
10. Collins, C. R., C. Withers-Martinez, G. A. Bentley, A. H. Batchelor, A. W. Thomas, and M. J. Blackman. 2007. Fine mapping of an epitope recognized by an invasion-inhibitory monoclonal antibody on the malaria vaccine candidate apical membrane antigen 1. J. Biol. Chem. 282:7431-7441.
11. Collins, W. E., D. Pye, P. E. Crewther, K. L. Vandenberg, G. G. Galland, A. J. Sulzer, D. J. Kemp, S. J. Edwards, R. L. Coppel, J. S. Sullivan, C. L. Morris, and R. F. Anders. 1994. Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am. J. Trop. Med. Hyg. 51:711-719.
12. Crewther, P. E., M. L. S. M. Matthew, R. H. Flegg, and R. F. Anders. 1996. Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes. Infect. Immun. 64:3310-3317.
13. Daly, T. M., and C. A. Long. 1995. Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. J. Immunol. 155:236-243.
14. Darko, C. A., E. Angov, W. E. Collins, E. S. Bergmann-Leitner, A. S. Girouard, S. L. Hitt, J. S. McBride, C. L. Diggs, A. A. Holder, C. A. Long, J. W. Barnwell, and J. A. Lyon. 2005. The clinical grade 42 kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic stage parasites. Infect. Immun. 73:287-297.
15. Dicko, A., D. J. Diemert, I. Sagara, M. Sogoba, M. B. Niambele, M. H. Assadou, O. Guindo, B. Kamate, M. Baby, M. Sissoko, E. M. Malkin, M. P. Fay, M. A. Thera, K. Miura, A. Dolo, D. A. Diallo, G. E. Mullen, C. A. Long, A. Saul, O. Doumbo, and L. H. Miller. 2007. Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians. PLoS One 10:e1045.
16. Dodoo, D., F. M. Omer, J. Todd, B. D. Akanmori, K. A. Korman, and E. M. Riley. 2001. Absolute levels and ratios of proinflammatory and anti-inflammatory cytokine production in vitro predict clinical immunity to Plasmodium falciparum malaria. J. Infect. Dis. 185:971-979.
17. Galinsky, M. R., A. R. Dluzewski, and J. W. Barnwell. 2005. A mechanistic approach to merozoite invasion of red blood cells: merozoite biogenesis, rupture, and invasion of erythrocytes, p. 113-168. In I. W. Sherman (ed.), Molecular approaches to malaria. ASM Press, Washington, DC.
18. Genton, B., and Z. H. Reed. 2007. Asexual blood-stage malaria vaccine development: facing the challenges. Curr. Opin. Infect. Dis. 20:467-475.
19. Grun, J. L., and W. P. Weidanz. 1981. Immunity to Plasmodium chabaudi adami in the B cell deficient mouse. Nature 290:143-145.
20. Guevera Patiño, J. A., A. A. Holder, J. S. McBride, and M. J. Blackman. 1997. Antibodies that inhibit merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. J. Exp. Med. 186:1689-1699.
21. Hay, S. I., C. A. Guerra, A. J. Tatem, A. M. Noor, and R. W. Snow. 2004. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect. Dis. 4:327-336.
22. Hirunpetcharat, C., P. Vukovic, X. Q. Liu, D. C. Kaslow, L. H. Miller, and M. F. Good. 1999. Absolute requirement for an active immune response involving B cells and Th cells in immunity to Plasmodium yoelii passively acquired with antibodies to the 19-kDa carboxyl-terminal fragment of merozoite surface protein-1. J. Immunol. 162:7309-7314.
23. Hodder, A. N., P. E. Crewther, and R. F. Anders. 2002. Specificity of the protective antibody response to apical membrane antigen-1. Infect. Immun. 69:3286-3294.
24. Holder, A. A., and R. R. Freeman. 1984. The three major antigens on the surface of Plasmodium falciparum merozoites are derived from a single high molecular weight precursor. J. Exp. Med. 160:624-629.
25. Kumar, S., A. Yadava, D. B. Keister, J. H. Tian, M. Ohl, K. A. Perdue-Greenfield, L. H. Miller, and D. C. Kaslow. 1995. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Mol. Med. 1:325-332.
26. Li, X., H. Chen, T. H. Oo, T. M. Daly, L. W. Bergman, S. C. Liu, A. H. Chishti, and S. S. Oh. 2004. A co-ligand complex anchors Plasmodium falciparum merozoites to the erythrocyte invasion receptor band 3. J. Biol. Chem. 279:5765-5771.
27. 42 is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses. PLoS One 3:e2830.
28. Mahanty, S., A. Saul, and L. H. Miller. 2003. Progress in the development of recombinant and synthetic blood-stage malaria vaccines. J. Exp. Biol. 206:3781-3788.
29. Majarian, W. M., T. M. Daly, W. P. Weidanz, and C. A. Long. 1984. Passive immunization against murine malaria with an IgG3 monoclonal antibody. J. Immunol. 132:3131-3137.
30. 42) vaccines for Plasmodium falciparum malaria. PLoS Clin. Trials 2:e12.
31. Malkin, E. M., D. J. Diemert, J. H. McArthur, J. R. Perreault, A. P. Miles, B. K. Giersing, G. E. Mullen, A. Orcutt, O. Muratova, M. Awkal, H. Zhou, J. Wang, A. Stowers, C. A. Long, S. Mahanty, L. H. Miller, A. Saul, and A. P. Durbin. 2005. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum. Infect. Immun. 73:3677-3685.
32. McBride, J. S., and H. G. Heidrich. 1987. Fragments of the polymorphic Mr 185,000 glycoprotein from the surface of isolated Plasmodium falciparum merozoites form an antigenic complex. Mol. Biochem. Parasitol. 23:71-84.
33. McIntosh, R. S., J. Shi, R. M. Jennings, J. C. Chappel, T. F. de Koning-Ward, T. Smith, J. Green, M. van Egmond, J. H. Leusen, M. Lazarou, J. van de Winkel, T. S. Jones, B. S. Crabb, A. A. Holder, and R. J. Pleass. 2007. The importance of human FcγRI in mediating protection to malaria. PLoS Pathog. 3:e72.
34. Mello, K., T. M. Daly, J. Morrissey, A. B. Vaidya, C. A. Long, and L. W. Bergman. 2002. A multigene family that interacts with the amino terminus of Plasmodium MSP-1 identified using the yeast two-hybrid system. Eukaryot. Cell 1:915-925.
35. Ockenhouse, C. F., E. Angov, K. E. Kester, C. Diggs, L. Soisson, J. F. Cummings, V. A. Stewart, D. R. Palmer, B. Mahajan, U. Krzych, N. Tornieporth, M. Delchambre, M. Vanhandenhove, O. Ofori-Anyinam, J. Cohen, J. A. Lyon, D. G. Heppner, and the MSP-1 Working Group. 2006. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine 24:3009-3017.
36. 19 across distantly related Plasmodium species. Nat. Med. 6:91-95.
37. 19 are a major component of the invasion-inhibitory response in individuals immune to malaria. J. Exp. Med. 193:1403-1412.
38. Omer, F. M., J. B. De Souza, and E. M. Riley. 2003. Differential induction of TGF-β regulates proinflammatory cytokine production and determines the outcome of lethal and non-lethal Plasmodium yoelii infections. J. Immunol. 171:5430-5436.
39. Othoro, C., A. A. Lal, B. Nahlen, D. Koech, A. S. Orago, and V. Udhayakumar. 1999. A low IL-10:TNF-α ratio is associated with malaria anemia in children residing in a holoendemic malaria region in Western Kenya. J. Infect. Dis. 179:279-282.
40. Pachebat, J. A., I. T. Ling, M. Grainger, C. Trucco, S. Howell, D. Fernandez-Reyes, R. Gunaratne, and A. A. Holder. 2001. The 22 kDa component of the protein complex on the surface of Plasmodium falciparum merozoites is derived from a larger precursor, merozoite surface protein 7. Mol. Biochem. Parasitol. 117:83-89.
41. Petritus, P. M., and J. M. Burns, Jr. 2008. Suppression of lethal Plasmodium yoelii malaria following protective immunization requires antibody-, IL-4-, and IFN-γ-dependent responses induced by vaccination and/or challenge infection. J. Immunol. 180:444-453.
42. Polhemus, M. E., A. J. Magill, J. F. Cummings, K. E. Kester, C. F. Ockenhouse, D. E. Lanar, S. Dutta, A. Barbosa, L. Soisson, C. L. Diggs, S. A. Robinson, J. D. Haynes, V. A. Stewart, L. A. Ware, C. Brando, U. Krzych, R. A. Bowden, J. D. Cohen, M. C. Dubois, O. Ofori-Anyinam, E. De-Kock, W. R. Ballou, and D. G. Heppner, Jr. 2007. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane antigen (AMA1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research. Vaccine 25:4203-4212.
43. Pullen, G. R., M. G. Fitzgerald, and C. S. Hosking. 1986. Antibody avidity determination by ELISA using thiocyanate elution. J. Immunol. Methods 83:83-87.
44. Sanders, P. R., G. T. Cantin, D. C. Greenbaum, P. R. Gilson, T. Nebl, R. L. Moritz, J. R. Yates III, A. N. Hodder, and B. S. Crabb. 2007. Identification of protein complexes in detergent-resistant membranes of Plasmodium falciparum schizonts. Mol. Biochem. Parasitol. 154:148-157.
45. Singh, S., K. Miura, H. Zhou, O. Muratova, B. Keegan, A. Miles, L. B. Martin, A. J. Saul, L. H. Miller, and C. A. Long. 2006. Immunity to recombinant Plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect. Immun. 74:4573-4580.
46. Spencer Valero, L. M., S. A. Ogun, S. L. Fleck, I. T. Ling, T. J. Scott-Finnigan, M. J. Blackman, and A. A. Holder. 1998. Passive immunization with antibodies against three distinct epitopes on Plasmodium yoelii merozoite surface protein 1 suppresses parasitemia. Infect. Immun. 66:3925-3930.
47. Stoute, J. A., J. Gombe, M. R. Withers, J. Siangla, D. McKinney, M. Onyango, J. F. Cummings, J. Milman, K. Tucker, L. Soisson, V. A. Stewart, J. A. Lyon, E. Angov, A. Leach, J. Cohen, K. E. Kester, C. F. Ockenhouse, C. A. Holland, C. L. Diggs, J. Wittes, D. G. Heppner, Jr., and the MSP-1 Malaria Vaccine Working Group. 2006. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Vaccine 25:176-184.
48. Stowers, A. W., M. C. Kennedy, B. P. Keegan, A. Saul, C. A. Long, and L. H. Miller. 2002. Vaccination of monkeys with recombinant P. falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect. Immun. 70:6961-6967.
49. Thera, M. A., O. K. Doumbo, D. Coulibaly, D. A. Diallo, I. Sagara, A. Dicko, D. J. Diemert, D. G. Heppner, Jr., V. A. Stewart, E. Angov, L. Soisson, A. Leach, K. Tucker, K. E. Lyke, C. V. Plowe, and the Mali FMP1 Working Group. 2006. Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial. PLoS Clin. Trials 1:e34.
50. Triglia, T., J. Healer, S. R. Caruana, A. N. Hodder, R. F. Anders, B. S. Crabb, and A. F. Cowman. 2000. Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species. Mol. Microbiol. 38:706-718.
51. Trucco, C., D. Fernandez-Reyes, S. Howell, W. H. Stafford, T. J. Scott-Finnigan, M. Grainger, S. A. Ogun, W. R. Taylor, and A. A. Holder. 2001. The merozoite surface protein 6 gene codes for a 36 kDa protein associated with the Plasmodium falciparum merozoite surface protein-1 complex. Mol. Biochem. Parasitol. 112:91-101.
52. Uthaipibull, C., B. Aufiero, S. E. H. Syed, B. Hansen, J. A. Guevara Patiño, E. Angov, I. T. Ling, K. Fegeding, W. D. Morgan, C. Ockenhouse, B. Birdsall, J. Feeney, J. A. Lyon, and A. A. Holder. 2001. Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum. J. Mol. Biol. 307:1381-1394.
53. van der Heyde, H. C., D. Huszar, C. Woodhouse, D. D. Manning, and W. P. Weidanz. 1994. The resolution of acute malaria in a definitive model of B cell deficiency, the JHD mouse. J. Immunol. 152:4557-4562.
54. von der Weid, T., N. Honarvar, and J. Langhorne. 1996. Gene-targeted mice lacking B cells are unable to eliminate a blood stage malaria infection. J. Immunol. 156:2510-2516.
55. + regulatory T cells correlates with more rapid parasite growth in human malaria infection. Immunity 23:287-296.
56. Withers, M. R., D. McKinney, B. R. Ogutu, J. N. Waitumbi, J. B. Milman, O. J. Apollo, O. G. Allen, K. Tucker, L. A. Soisson, C. Diggs, A. Leach, J. Wittes, F. Dubovsky, V. A. Stewart, S. A. Remich, J. Cohen, W. R. Ballou, C. A. Holland, J. A. Lyon, E. Angov, J. A. Stoute, S. K. Martin, D. G. Heppner, Jr., and the MSP-1 Malaria Vaccine Working Group. 2006. Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children. PLoS Clin. Trials 1:e32.
57. Yuen, D., W. H. Leung, R. Cheung, C. Hashimoto, S. F. Ng, W. Ho, and G. Hui. 2007. Antigenicity and immunogenicity of the N-terminal 33 kDa processed fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development. Vaccine 25:490-499.